Previous 10 |
BOSTON , Sept. 13, 2018 /PRNewswire/ -- The ten John Hancock closed-end funds listed below announced today that each fund's Annual Meeting of Shareholders ("Annual Meeting") will be held on February 7, 2019 , at 2:00 p.m., Eastern Time , at the offices of the funds, 197 Clare...
With the Federal Reserve's 2018 Jackson Hole Economic Symposium now over, markets continuing to hit new highs, and the economy seemingly humming on all cylinders (lots of people are employed, corporate profits are strong, and the Q2 gross national product was just north of 4%), we thought it w...
BOSTON , Aug. 31, 2018 /PRNewswire/ -- John Hancock Tax-Advantaged Dividend Income Fund (NYSE: HTD) (the "Fund"), a closed-end fund managed by John Hancock Advisers, LLC and subadvised by both John Hancock Asset Management a division of Manulife Asset Management (US) LLC, and Analytic Inv...
John Hancock Preferred Income Fund (NYSE: HPI ) - $0.1400. John Hancock Preferred Income Fund II (NYSE: HPF ) - $0.1400. John Hancock Preferred Income Fund III (NYSE: HPS ) - $0.1222. John Hancock Premium Dividend Fund (NYSE: PDT ) - $0.0975. John Hancock Tax-Advantaged Dividend Inco...
BOSTON , Aug. 22, 2018 /PRNewswire/ -- The five John Hancock closed-end funds listed below declared their monthly distributions today as follows: John Hancock Premium Dividend Fund Premium Dividend Fund (the "Fund") declared...
News, Short Squeeze, Breakout and More Instantly...
John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest Company Name:
HTD Stock Symbol:
NYSE Market:
2024-07-12 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 05:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Results from the CATALYST clinical trial were presented at the American Diabetes Association’s 84 th Scientific Sessions at a featured plenary session titled: “Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes” With 1,055 patients enro...